secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001213900-24-042937
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q1 revenue +51% to $19.7M; Adj EBITDA improves to $(0.3)M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Revenue $19.7M, +51% YoY; gross profit $12.2M, +64% YoY.
- GAAP net loss $(6.9)M ($0.38/share); Non-GAAP net loss $(2.0)M ($0.11/share).
- Adjusted EBITDA improved to $(0.3)M from $(2.2)M a year ago.
- Won 9 DAAP (AI-platform) deals in Q1; Net Revenue Retention 116% vs 86%.
- Reiterated FY2024 guidance: revenue at least $100M, Adj EBITDA at least $11M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024042937/0001213900-24-042937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024042937/ea0206046-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer